DK1043982T3 - Lipasehammende polymerer - Google Patents

Lipasehammende polymerer

Info

Publication number
DK1043982T3
DK1043982T3 DK99901332T DK99901332T DK1043982T3 DK 1043982 T3 DK1043982 T3 DK 1043982T3 DK 99901332 T DK99901332 T DK 99901332T DK 99901332 T DK99901332 T DK 99901332T DK 1043982 T3 DK1043982 T3 DK 1043982T3
Authority
DK
Denmark
Prior art keywords
polymers
inhibiting polymers
lipase inhibiting
patient
methods
Prior art date
Application number
DK99901332T
Other languages
Danish (da)
English (en)
Inventor
W Harry Mandeville Iii
Venkata R Garigapati
Molly Kate Boie
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of DK1043982T3 publication Critical patent/DK1043982T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
DK99901332T 1998-01-09 1999-01-06 Lipasehammende polymerer DK1043982T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US537998A 1998-01-09 1998-01-09
US09/166,510 US6267952B1 (en) 1998-01-09 1998-10-05 Lipase inhibiting polymers

Publications (1)

Publication Number Publication Date
DK1043982T3 true DK1043982T3 (da) 2006-02-13

Family

ID=26674279

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99901332T DK1043982T3 (da) 1998-01-09 1999-01-06 Lipasehammende polymerer

Country Status (20)

Country Link
US (6) US6267952B1 (de)
EP (1) EP1043982B1 (de)
JP (1) JP2002500182A (de)
KR (1) KR100620634B1 (de)
CN (2) CN1287489A (de)
AT (1) ATE308979T1 (de)
AU (1) AU747016B2 (de)
BR (1) BR9907233A (de)
CA (1) CA2318416A1 (de)
DE (1) DE69928219T2 (de)
DK (1) DK1043982T3 (de)
ES (1) ES2253872T3 (de)
HK (1) HK1079706A1 (de)
HU (1) HUP0101128A3 (de)
IL (1) IL137098A (de)
NO (1) NO20003511L (de)
NZ (1) NZ505296A (de)
PL (1) PL193453B1 (de)
RU (1) RU2207861C2 (de)
WO (1) WO1999034786A2 (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267952B1 (en) * 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
EP1212097B1 (de) * 1999-09-10 2005-11-16 The Procter & Gamble Company Enzyminhibitoren
EP1212098A2 (de) * 1999-09-10 2002-06-12 The Procter & Gamble Company Enzyminhibitoren
AR025609A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
AR025587A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
EP1132389A1 (de) 2000-03-06 2001-09-12 Vernalis Research Limited Neue Azaindolyl-Derivate für die Behandlung von Fettleibigheit
AU2001281846B2 (en) * 2000-06-27 2006-04-27 Cheplapharm Arzneimittel Gmbh Method for preparing a composition
CN100423715C (zh) 2000-07-28 2008-10-08 霍夫曼-拉罗奇有限公司 新型药物组合物
BR0112800A (pt) 2000-07-28 2003-07-01 Hoffmann La Roche Utilização de um inibidor de lìpases e de um sequestrante de ácido de bìlis farmaceuticamente aceitáveis e processo para a prevenção e tratamento de enfermidades associadas com altos nìveis de colesterol de plasma
CA2417607C (en) 2000-08-09 2008-01-29 Christine Feinle Lipase inhibitors for the treatment of dyspepsia
US6900226B2 (en) 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ES2266258T3 (es) * 2000-09-15 2007-03-01 Vertex Pharmaceuticals Incorporated Compuestos de pirazol utiles como inhibidores de proteina cinasas.
JP4047723B2 (ja) 2000-10-16 2008-02-13 エフ．ホフマン−ラ ロシュ アーゲー インドリン誘導体、および５−ｈｔ２受容体リガンドとしてのその使用
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
EP1345925B1 (de) * 2000-12-21 2006-05-17 Vertex Pharmaceuticals Incorporated Pyrazolverbindungen als proteinkinasehemmer
EP1347979B1 (de) 2000-12-27 2007-08-08 F. Hoffmann-La Roche Ag Indolderivate und deren verwendung als 5-ht2b- und 5-ht2c-rezeptorliganden
GB0106177D0 (en) 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
KR100621287B1 (ko) 2001-05-21 2006-09-13 에프. 호프만-라 로슈 아게 신경 펩타이드 ｙ 수용체에 대한 리간드로서의 퀴놀린유도체
US20030027786A1 (en) 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US6787558B2 (en) 2001-09-28 2004-09-07 Hoffmann-La Roche Inc. Quinoline derivatives
GB0202015D0 (en) 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
JP4216196B2 (ja) 2002-02-04 2009-01-28 エフ．ホフマン−ラ ロシュ アーゲー Ｎｐｙアンタゴニストとしてのキノリン誘導体
RU2004126671A (ru) * 2002-02-06 2005-04-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Гетероарилсоединения, полезные в качестве ингибиторов gsk-3
MXPA04008031A (es) * 2002-02-19 2004-11-26 Procter & Gamble Nueva lipasa fungica.
RU2004129285A (ru) 2002-02-28 2005-10-27 Ф.Хоффманн-Ля Рош Аг (Ch) Производные тиазола в качестве антагонистов рецептора npy
EP1485380B1 (de) * 2002-03-15 2010-05-19 Vertex Pharmaceuticals Incorporated Azolylaminoazine als proteinkinasehemmer
AU2003223930A1 (en) * 2002-06-14 2003-12-31 Novo Nordisk A/S Pharmaceutical use of boronic acids and esters thereof
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
EP1560816A1 (de) 2002-07-05 2005-08-10 F. Hoffmann-La Roche Ag Chinazoline derivate
ES2273043T3 (es) * 2002-08-02 2007-05-01 Vertex Pharmaceuticals Incorporated Composiciones de pirazol utiles como inhibidores de gsk-3.
AU2003253364B2 (en) 2002-08-07 2007-06-07 F. Hoffmann-La Roche Ag Thiazole derivatives
CA2546696A1 (en) * 2002-11-19 2004-06-03 Genzyme Corporation Polymeric boronic acid derivatives as lipase inhibitors
WO2004072029A2 (en) * 2003-02-06 2004-08-26 Vertex Pharmaceuticals Incorporated Pyrazolopyridazines useful as inhibitors of protein kinases
GB0314967D0 (en) 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
RU2006107444A (ru) 2003-08-12 2007-09-20 Ф.Хоффманн-Ля Рош Аг (Ch) 2-амино-5-бензоилтиазолы в качестве антагонистов npy
CA2533464A1 (en) 2003-08-12 2005-02-17 F. Hoffmann-La Roche Ag Thiazole derivatives as npy antagonists
US20050239859A2 (en) * 2003-09-03 2005-10-27 Solvay Pharmaceuticals Gmbh Novel medical uses of 4,5-dihydro-1h-pyrazole derivatives having cb1- antagonistic activity
US20050143441A1 (en) * 2003-10-27 2005-06-30 Jochen Antel Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
US20050124660A1 (en) * 2003-10-27 2005-06-09 Jochen Antel Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
JP4691041B2 (ja) 2003-11-20 2011-06-01 チルドレンズ ホスピタル メディカル センター Ｇｔｐアーゼ阻害剤および使用方法
US7592340B2 (en) * 2003-12-04 2009-09-22 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
US7462394B2 (en) * 2004-05-06 2008-12-09 Ppg Industries Ohio, Inc. Method of stabilizing metal pigments against gassing
CN101974125B (zh) * 2004-07-30 2013-09-18 巴斯夫欧洲公司 聚合物硼酸衍生物及其在造纸中的用途
MX2007004889A (es) * 2004-10-25 2007-09-11 Solvay Pharm Gmbh Composiciones farmaceuticas que comprenden antagonistas del receptor cannabinoide cb1 y activadores de canales de potasio para el tratamiento de la diabetes mellitus tipo i, la obesidad y trastornos relacionados.
AU2006243243B2 (en) 2005-05-03 2009-05-14 F. Hoffmann-La Roche Ag Tetracyclic azapyrazinoindolines as 5-HT2 ligands
AU2006275528B2 (en) 2005-07-29 2012-03-08 Children's Hospital Medical Center GTPase inhibitors and methods of use and crystal structure of Rac-1 GTPase
CA2619517A1 (en) * 2005-08-18 2007-02-22 Michael Mortimore Pyrazine kinase inhibitors
EP1945635B1 (de) 2005-08-18 2009-05-06 F.Hoffmann-La Roche Ag Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
AR056499A1 (es) * 2005-09-06 2007-10-10 Serapis Farmaceuticals Ltd Compuestos
WO2007056163A2 (en) * 2005-11-03 2007-05-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
EP1968967B1 (de) 2005-11-30 2011-04-27 F. Hoffmann-La Roche AG 1,1-dioxo-thiomorpholinyl-indolyl-methanon-derivate zur verwendung als h3-modulatoren
WO2007063000A1 (en) 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag 5-substituted indole-2-carboxamide derivatives
WO2007062999A2 (en) 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag 1,5-substituted indol-2-yl amide derivatives
WO2007065820A1 (en) 2005-12-09 2007-06-14 F. Hoffmann-La Roche Ag Tricyclic amide derivatives useful for treating obesity
WO2007068620A1 (en) 2005-12-15 2007-06-21 F. Hoffmann-La Roche Ag Pyrrolo[2,3-c]pyridine derivatives
JP2009519293A (ja) 2005-12-16 2009-05-14 エフ．ホフマン−ラ ロシュ アーゲー Ｈ３レセプター調節剤としてのピロロ［２，３−ｂ］ピリジン誘導体
US7432255B2 (en) 2006-05-16 2008-10-07 Hoffmann-La Roche Inc. 1H-indol-5-yl-piperazin-1-yl-methanone derivatives
US7902184B2 (en) 2006-05-30 2011-03-08 Hoffmann-La Roche Inc. Piperazinyl pyrimidine derivatives
US7514433B2 (en) 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives
MX2009004807A (es) * 2006-11-02 2009-06-15 Vertex Pharma Aminopiridinas y aminopirimidinas utiles como inhibidores de proteina cinasa.
US20080146559A1 (en) 2006-12-08 2008-06-19 Li Chen 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives
JP2010513567A (ja) * 2006-12-19 2010-04-30 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼの阻害剤として有用なアミノピリミジン
ATE526328T1 (de) * 2007-03-09 2011-10-15 Vertex Pharma Als inhibitoren von proteinkinasen geeignete aminopyrimidine
WO2008112642A1 (en) * 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
WO2008112646A1 (en) * 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyridines useful as inhibitors of protein kinases
CA2683785A1 (en) 2007-04-13 2008-10-23 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
CA2685876A1 (en) 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
MX2009011811A (es) * 2007-05-02 2010-01-14 Vertex Pharma Aminopirimidinas utiles como inhibidores de cinasa.
MX2009011812A (es) * 2007-05-02 2010-01-14 Vertex Pharma Aminopirimidinas utiles como inhibidores de cinasa.
CN101687852A (zh) * 2007-05-24 2010-03-31 沃泰克斯药物股份有限公司 可用作激酶抑制剂的噻唑类和吡唑类化合物
EP2183237A1 (de) 2007-07-25 2010-05-12 F. Hoffmann-Roche AG Benzofuran- und benzo[b]thiophen-2-carbonsäureamidderivate und deren verwendung als modulatoren des histamin-3-rezeptors
AR067762A1 (es) * 2007-07-31 2009-10-21 Vertex Pharma Proceso para preparar 5-fluoro-1h-pirazolo (3,4-b) piridin-3-amina y derivados de la misma
US8185398B2 (en) * 2007-12-31 2012-05-22 Intel-Ge Care Innovations Llc Reading device with shortcut read function
KR20110050549A (ko) * 2008-09-03 2011-05-13 버텍스 파마슈티칼스 인코포레이티드 공-결정 및 이를 포함하는 제약 제제
JP2013521796A (ja) * 2010-03-13 2013-06-13 イーストポンド・ラボラトリーズ・リミテッド 脂肪結合性組成物
CN102199172A (zh) * 2010-03-24 2011-09-28 金凯美(大连)医药科技有限公司 一种1-取代亚磷酰二氯的制备方法
US9980942B2 (en) 2012-05-02 2018-05-29 Children's Hospital Medical Center Rejuvenation of precursor cells
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
EP4013402B1 (de) 2019-08-16 2024-11-06 Children's Hospital Medical Center Cdc-42-inhibitoren zur verwendung bei der behandlung von altersverbundener depression, sarkopenie oder gebrechlichkeit

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7017227A (de) 1969-12-27 1971-06-29
US4211765A (en) * 1971-10-12 1980-07-08 Monsanto Company Method for controlling obesity
US3923972A (en) 1971-10-12 1975-12-02 Monsanto Co Method of lowering blood cholesterol level
IT1052819B (it) 1975-12-12 1981-07-20 Fargal Pharmasint Lab Biochim Preparato inibitore dell assorbimento dei lipidi a base di dietilamminoetildestrano
US4265879A (en) 1977-09-13 1981-05-05 Monsanto Company Method for controlling blood triglycerides
US4218443A (en) 1979-01-15 1980-08-19 Hoffmann-La Roche Inc. Polyether ionophores as antiobesity and hypotriglyceridemic agents
US4302450A (en) 1979-01-15 1981-11-24 Hoffmann-La Roche Inc. Polyether ionophores as antiobesity and hypotriglyceridemic agents
US4432968A (en) 1980-10-20 1984-02-21 The Dow Chemical Company Weight control with fat imbibing polymers
AU7653081A (en) 1980-10-20 1982-04-29 Dow Chemical Company, The T-butylstyrene copolymers for controlling body weight of animals
US5597810A (en) 1984-12-27 1997-01-28 Hoffman; Allan S. Method for reducing absorption of undesired lipids in the gastrointestinal tract
US5200183A (en) 1987-11-19 1993-04-06 Oklahoma Medical Research Foundation Recombinant bile salt activated lipases
US5089163A (en) 1989-01-30 1992-02-18 Lever Brothers Company, Division Of Conopco, Inc. Enzymatic liquid detergent composition
US4959179A (en) 1989-01-30 1990-09-25 Lever Brothers Company Stabilized enzymes liquid detergent composition containing lipase and protease
US5063210A (en) 1989-04-20 1991-11-05 Lange Iii Louis G Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption
US5484777A (en) 1989-04-20 1996-01-16 Lange, Iii; Louis G. Pancreatic cholesterol esterase inhibitor
US5674482A (en) 1989-08-14 1997-10-07 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Polymers with alkyl- or heteroalkyl -aryl backbone and pharmaceutical compositions incorporating same
JP3100057B2 (ja) 1989-08-29 2000-10-16 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 新規な加水分解酵素阻害剤及び基質、並びにこれらを用いた分析方法及びキット
US5308766A (en) 1989-08-29 1994-05-03 The Regents Of The University Of California Hydrolytic enzyme inhibitors/inactivators and methods for using same
US5376640A (en) * 1989-12-25 1994-12-27 Nisshin Flour Milling Co., Ltd. Lipolytic enzyme inhibitors
US5260310A (en) 1990-02-26 1993-11-09 Hoffmann-La Roche Inc. Oxetanone compounds and pharmaceutical compositions containing them
DK244090D0 (da) 1990-10-09 1990-10-09 Novo Nordisk As Kemiske forbindelser
US5137716A (en) 1990-11-15 1992-08-11 Weisenfeld Michael S Method of reducing weight in mammals
EP0622078B1 (de) 1992-01-14 1999-09-01 Hisamitsu Pharmaceutical Co., Inc. Cholesterinspiegelsenkendes mittel
CA2063499C (en) 1992-03-19 1996-06-18 Leon Edward St. Pierre Ingestible polymeric phosphonium salts for the lowering of blood cholesterol
JP2667351B2 (ja) 1992-03-24 1997-10-27 麒麟麦酒株式会社 食餌脂質消化吸収阻害剤および飲食品
DE59300925D1 (de) 1992-03-28 1995-12-21 Hoechst Ag Arzneimittel aus Polyhydroxymethylenderivaten, Verfahren zu deren Herstellung und Verwendung.
RU2066185C1 (ru) * 1993-01-11 1996-09-10 Институт пищевых веществ РАН Гиполипидемический энтеросорбент
US5624963A (en) 1993-06-02 1997-04-29 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5703188A (en) 1993-06-02 1997-12-30 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5607669A (en) 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5618530A (en) 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5569452A (en) 1993-08-31 1996-10-29 Tsrl, Inc. Pharmaceutical formulation having enhanced bile acid binding affinity
US5414068A (en) 1994-01-24 1995-05-09 Rohm And Haas Company Crosslinked anion exchange particles and method for producing the particles
TW474813B (en) 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US5474993A (en) 1994-06-14 1995-12-12 Sterling Winthrop, Inc. Lactam inhibitors of cholesterol esterase
JPH0859458A (ja) 1994-08-25 1996-03-05 Zeria Pharmaceut Co Ltd インダン誘導体を含有する高脂血症治療剤
JP3532999B2 (ja) 1995-03-24 2004-05-31 株式会社ロッテ 新規なタンニン類およびこれを有効成分とするリパーゼ阻害剤
US5993675A (en) * 1997-12-31 1999-11-30 Hagerthy; Albert P. Fuel-water separator for marine and diesel engines
NZ505294A (en) * 1998-01-09 2003-02-28 Geltex Pharma Inc Use of fat-binding polymers in combination with one or more lipase inhibitors to treat obesity and hypertriglyceridemia and for reducing the absorption of dietary fat in mammals, and the use of fat-binding polymers to treat steatorrhea
US6299868B1 (en) * 1999-07-14 2001-10-09 Geltex Pharmaceuticals, Inc. Fat-binding polymers
US6267952B1 (en) * 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
US5942500A (en) * 1998-04-27 1999-08-24 Perry; Stephen C. Dietary composition to reduce dietary fats

Also Published As

Publication number Publication date
NZ505296A (en) 2002-12-20
US6352692B1 (en) 2002-03-05
BR9907233A (pt) 2000-10-17
HK1079706A1 (zh) 2006-04-13
US20050085535A1 (en) 2005-04-21
IL137098A0 (en) 2001-06-14
IL137098A (en) 2006-07-05
PL344022A1 (en) 2001-09-24
WO1999034786A3 (en) 2000-02-03
NO20003511L (no) 2000-09-07
DE69928219T2 (de) 2006-07-27
US6875428B2 (en) 2005-04-05
EP1043982B1 (de) 2005-11-09
US6267952B1 (en) 2001-07-31
AU2105699A (en) 1999-07-26
US20030185789A1 (en) 2003-10-02
CA2318416A1 (en) 1999-07-15
ES2253872T3 (es) 2006-06-01
US6558657B1 (en) 2003-05-06
CN1287489A (zh) 2001-03-14
NO20003511D0 (no) 2000-07-07
DE69928219D1 (de) 2005-12-15
AU747016B2 (en) 2002-05-09
KR20010034012A (ko) 2001-04-25
RU2207861C2 (ru) 2003-07-10
HUP0101128A3 (en) 2003-01-28
KR100620634B1 (ko) 2006-09-13
US6572850B1 (en) 2003-06-03
CN1636574A (zh) 2005-07-13
ATE308979T1 (de) 2005-11-15
HUP0101128A2 (hu) 2002-01-28
WO1999034786A2 (en) 1999-07-15
JP2002500182A (ja) 2002-01-08
EP1043982A2 (de) 2000-10-18
PL193453B1 (pl) 2007-02-28

Similar Documents

Publication Publication Date Title
NO20003511D0 (no) Lipase-inhiberende polymerer
ATE493502T1 (de) Glucosamin und verfahren zur herstellung von glucosamin aus mikrobieller biomasse
ATE283830T1 (de) Verfahren zur behandlung von glassubstraten und glassubstraten zur herstellung von anzeigeschirmen
AU5630999A (en) Endofucanases and method using same for preparing fuco-oligosaccharides from fucanes, bacterium producing endofucanases and uses of fuco-oligosaccharides for plant protection
EP1569695A4 (de) Antisense-modulationder apolipoprotein-b-expression
MX2007002508A (es) Cepas que producen ferulato esterasa y metodos para usarlas.
DE602004018297D1 (de) Verfahren zur kollagenextraktion das mikrobielle fermentierung umfasst
ATE233491T1 (de) Verfahren und zusammensetzungen zur verbesserung der aeroben stabilität von silage
IL112061A0 (en) Methods for the preparation of taxanes
DE69825440D1 (de) VERWENDUNG VON TAUROLIDINE ZUR Herstellung eines Arzneimittels zur BEHANDLUNG VON LEUKÄMIEN
AU2001258373A1 (en) Method for identifying helicobacter antigens
AU5868698A (en) Specific pancreatic lipase inhibitors and their applications
EP1250347A4 (de) Antisense modulation der akt-3 expression
BR0316865A (pt) Variante de butirilcolinesterase, ácido nucleico, e, métodos para converter um derivado de camptotecina a um inibidor de topoisomerase, e para tratar câncer
ATE224149T1 (de) Verfahren zur herstellung von stabilen trüben extrakten
EA199800819A1 (ru) Способ лечения биполярного расстройства
DE69923559D1 (de) Methoden zur inhibierung von helicobacter pylori
ATE305515T1 (de) Nukleotidsequenzen kodierend fur proteine beteiligt an der biosynthese von l-serin, verbessertes verfahren zur mikrobiellen herstellung von l-serin sowie ein dazu geeigneter genetisch veranderter mikroorganismus
UA87984C2 (ru) Повышение уровней масла в растениях
WO2004009541A3 (en) Antisense modulation of endothelial lipase expression
ATE214911T1 (de) Verwendung von mikroorganismen extrakten in kosmetischen oder pharmazeutischen zusammensetzungen
PT1129206E (pt) Dissolucao de substancias residuais de fermentacao
DE50010752D1 (de) Biotechnologisches verfahren zur herstellung von n-acetylmannosamin
ATE316146T1 (de) Verfahren zur herstellung von pravastatin- natriumsalz mittels streptomyces flavidovirens dsm 14455
UA21844A (uk) Спосіб приготуваhhя біологічhо активhого муміє